Burton Elias Sobel, MD: a conversation with the editor. Interview by William Clifford Roberts.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  American Journal of Cardiology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/s0002-9149(98)00892-3PMID 10072235
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The retardation of vasculopathy induced by attenuation of insulin resistance in the corpulent JCR:LA-cp rat is reflected by decreased vascular smooth muscle cell proliferation in vivo.

  1999cited by this paper
• Cardiovascular consequences of polycystic ovary syndrome.

  1999cited by this paper
• Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk.

  1999cited by this paper
• Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

  1998cited by this paper
• Induction of Hyperinsulinemia Combined With Hyperglycemia and Hypertriglyceridemia Increases Plasminogen Activator Inhibitor 1 in Blood in Normal Human Subjects

  1998cited by this paper
• Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.

  1997cited by this paper
• Differential effects of anticoagulants on the activation of platelets ex vivo.

  1997cited by this paper
• Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert.

  1996cited by this paper
• Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding.

  1996cited by this paper
• Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

  1995cited by this paper
• Intracranial bleeding, fibrinolysis, and anticoagulation. Causal connections and clinical implications.

  1994cited by this paper
• Factors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients

  1994cited by this paper
• Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.

  1993cited by this paper
• The Structure of Cardiological Revolutions James B. Herrick Lecture

  1993cited by this paper
• Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.

  1993cited by this paper
• Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1.

  1992cited by this paper
• Stimulation by Proinsulin of Expression of Plasminogen Activator Inhibitor Type-I in Endothelial Cells

  1992cited by this paper
• "Plasminogen steal" and clot lysis.

  1992cited by this paper
• Synergistic induction of plasminogen activator inhibitor type-1 in HEP G2 cells by thrombin and transforming growth factor-beta.

  1992cited by this paper
• Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease.

  1992cited by this paper
• Imaging of Thrombi With Tissue‐Type Plasminogen Activator Rendered Enzymatically Inactive and Conjugated to a Residualizing Label

  1992cited by this paper
• On-line assessment of ventricular function by automatic boundary detection and ultrasonic backscatter imaging.

  1992cited by this paper
• Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.

  1992cited by this paper
• Induction of Endothelial Cell Expression of the Plasminogen Activator Inhibitor Type 1 Gene by Thrombosis In Vivo

  1992cited by this paper
• Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis.

  1991cited by this paper
• Relative Efficacy of Antithrombin Compared With Antiplatelet Agents in Accelerating Coronary Thrombolysis and Preventing Early Reocclusion

  1991cited by this paper
• Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein‐Associated Coagulation Inhibitor

  1991cited by this paper
• The dependence of activation of platelets by a plasminogen activator on the evolution of thrombin activity.

  1991cited by this paper
• Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina.

  1991cited by this paper
• Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states

  1991cited by this paper
• Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis.

  1991cited by this paper
• Induction of Sustained Patency After Clot‐Selective Coronary Thrombolysis With Hybrid‐B, a Genetically Engineered Plasminogen Activator With a Prolonged Biological Half‐life

  1991cited by this paper
• Mediators of Induction of Augmented Expression of Plasminogen Activator Inhibitor Type-1 in Hep G2 Cells by Platelets

  1991cited by this paper
• Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor

  1991cited by this paper
• The nature of interactions between tissue-type plasminogen activator and platelets.

  1990cited by this paper
• Augmented myocardial perfusion reserve after coronary angioplasty quantified by positron emission tomography with H2(15)O.

  1990cited by this paper
• Induction of Synthesis of Plasminogen Activator Inhibitor Type-1 byTissue-Type Plasminogen Activator in Human Hepatic and Endothelial Cells

  1990cited by this paper
• Augmented and sustained plasma concentrations after intramuscular injections of molecular variants and deglycosylated forms of tissue-type plasminogen activators.

  1990cited by this paper
• Labeling of human clots in vitro with an active-site mutant of t-PA.

  1990cited by this paper
• Induction of plasminogen activator inhibitor by products released from platelets.

  1990cited by this paper
• Coronary thrombolysis and the new biology.

  1989cited by this paper
• Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.

  1989cited by this paper
• Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.

  1989cited by this paper
• Characterization of interaction of active-site serine mutants of tissue-type plasminogen activator with plasminogen activator inhibitor-1.

  1989cited by this paper
• Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infarction.

  1989cited by this paper
• Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.

  1989cited by this paper
• Ultrasonic tissue characterization with integrated backscatter. Acute myocardial ischemia, reperfusion, and stunned myocardium in patients.

  1989cited by this paper
• Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation.

  1989cited by this paper
• Early identification with ultrasonic integrated backscatter of viable but stunned myocardium in dogs.

  1989cited by this paper
• The Nature of Synergy between Tissue-Type and Single Chain Urokinase-Type Plasminogen Activators

  1989cited by this paper
• Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system.

  1988cited by this paper
• Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor.

  1988cited by this paper
• Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.

  1988cited by this paper
• Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2.

  1988cited by this paper
• Delineation of impaired regional myocardial perfusion by positron emission tomography with H2(15)O.

  1988cited by this paper
• Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).

  1988cited by this paper
• Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation.

  1988cited by this paper
• The temporal pattern of recovery of myocardial perfusion and metabolism delineated by positron emission tomography after coronary thrombolysis.

  1987cited by this paper
• Delineation of myocardial oxygen utilization with carbon-11-labeled acetate.

  1987cited by this paper
• Safety and efficacy of tissue-type plasminogen activator produced by recombinant DNA technology.

  1987cited by this paper
• Quantitative ultrasonic characterization of the nature of atherosclerotic plaques in human aorta.

  1987cited by this paper
• Sustained Fibrinolysis After Administration of t-PA Despite Its Short Half-Life in the Circulation

  1987cited by this paper
• Pharmacodynamics of tissue-type plasminogen activator characterized by computer-assisted simulation.

  1986cited by this paper
• Sensitive detection of the effects of reperfusion on myocardium by ultrasonic tissue characterization with integrated backscatter.

  1986cited by this paper
• External detection of beta-adrenoreceptors with 125I-hydroxybenzylpindolol in isolated perfused hearts.

  1986cited by this paper
• Early detection of myocardial reperfusion by assay of plasma MM-creatine kinase isoforms in dogs.

  1986cited by this paper
• Coronary thrombolysis with tissue-type plasminogen activator (t-PA): emerging strategies.

  1986cited by this paper
• Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis.

  1986cited by this paper
• Quantification of differences in frequency content of signal-averaged electrocardiograms in patients with compared to those without sustained ventricular tachycardia.

  1985cited by this paper
• Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.

  1985cited by this paper
• Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator.

  1985cited by this paper
• Early detection of myocardial infarction in conscious dogs by analysis of plasma MM creatine kinase isoforms.

  1985cited by this paper
• Efflux of metabolized and nonmetabolized fatty acid from canine myocardium. Implications for quantifying myocardial metabolism tomographically.

  1985cited by this paper
• Thrombolysis, clot selectivity, and kinetics.

  1984cited by this paper
• Amphipathic metabolites and membrane dysfunction in ischemic myocardium.

  1984cited by this paper
• Fast-Fourier transform analysis of signal-averaged electrocardiograms for identification of patients prone to sustained ventricular tachycardia.

  1984cited by this paper
• Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase.

  1984cited by this paper
• Coronary thrombolysis: pharmacological considerations with emphasis on tissue-type plasminogen activator (t-PA).

  1984cited by this paper
• Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.

  1984cited by this paper
• Quantification of regional myocardial blood flow in vivo with H215O.

  1984cited by this paper
• Scintigraphic detection of coronary artery thrombi in patients with acute myocardial infarction.

  1984cited by this paper
• Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.

  1984cited by this paper
• Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus.

  1984cited by this paper
• Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.

  1984cited by this paper
• Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study.

  1983cited by this paper
• Alpha adrenergic-mediated accumulation of calcium in reperfused myocardium.

  1983cited by this paper
• Arrhythmogenic properties of phospholipid metabolites associated with myocardial ischemia.

  1983cited by this paper
• Clot-selective coronary thrombolysis with tissue-type plasminogen activator.

  1983cited by this paper
• Mitochondrial dysfunction induced by fatty acid ethyl esters, myocardial metabolites of ethanol.

  1983cited by this paper
• Monitoring of cardiac antirejection therapy with In-111 lymphocytes.

  1982cited by this paper
• Detection of Cardiac Transplant Rejection with Radiolabeled Lymphocytes

  1982cited by this paper
• Effect of Flow‐Independent Reduction of Metabolism on Regional Myocardial Clearance of 11C‐Palmitate

  1982cited by this paper
• Pathophysiological concentrations of lysophosphatides and the slow response.

  1982cited by this paper
• Lysophosphatidylcholine metabolism in the rabbit heart. Characterization of metabolic pathways and partial purification of myocardial lysophospholipase-transacylase.

  1982cited by this paper
• Incorporation of Radiolabeled Lysophosphatidyl Choline into Canine Purkinje Fibers and Ventricular Muscle: Electrophysiological, Biochemical, and Autoradiographic Correlations

  1982cited by this paper
• Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography.

  1982cited by this paper
• "Redistribution" of myocardial thallium-201 without reperfusion: implications regarding absolute quantification of perfusion.

  1982cited by this paper
• Characterization of Nontransmural Myocardial Infarction by Positron‐emission Tomography

  1982cited by this paper
• Detection of ischemic myocardium in vivo through the chest wall by quantitative ultrasonic tissue characterization.

  1982cited by this paper
• Electrophysiological Effects of Amphiphiles on Canine Purkinje Fibers

  1981cited by this paper

• No citing papers are available for this paper.